JP2010539192A - ノロウイルスに対して防御免疫応答を付与する方法 - Google Patents

ノロウイルスに対して防御免疫応答を付与する方法 Download PDF

Info

Publication number
JP2010539192A
JP2010539192A JP2010525114A JP2010525114A JP2010539192A JP 2010539192 A JP2010539192 A JP 2010539192A JP 2010525114 A JP2010525114 A JP 2010525114A JP 2010525114 A JP2010525114 A JP 2010525114A JP 2010539192 A JP2010539192 A JP 2010539192A
Authority
JP
Japan
Prior art keywords
norovirus
vaccine
vlp
virus
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2010525114A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010539192A5 (enExample
Inventor
リチャードソン，チャールズ
ヴェドヴィック，トーマス，エス．
フォーベルト，トーマス，アール．
Original Assignee
リゴサイト ファーマスーティカルズ，インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40468754&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2010539192(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by リゴサイト ファーマスーティカルズ，インコーポレイテッド filed Critical リゴサイト ファーマスーティカルズ，インコーポレイテッド
Publication of JP2010539192A publication Critical patent/JP2010539192A/ja
Publication of JP2010539192A5 publication Critical patent/JP2010539192A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55583—Polysaccharides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/16011—Caliciviridae
    • C12N2770/16023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/16011—Caliciviridae
    • C12N2770/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
JP2010525114A 2007-09-18 2008-09-18 ノロウイルスに対して防御免疫応答を付与する方法 Pending JP2010539192A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US97338907P 2007-09-18 2007-09-18
US98682607P 2007-11-09 2007-11-09
PCT/US2008/076763 WO2009039229A2 (en) 2007-09-18 2008-09-18 Method of conferring a protective immune response to norovirus

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014095094A Division JP6296885B2 (ja) 2007-09-18 2014-05-02 ノロウイルスに対して防御免疫応答を付与する方法

Publications (2)

Publication Number Publication Date
JP2010539192A true JP2010539192A (ja) 2010-12-16
JP2010539192A5 JP2010539192A5 (enExample) 2011-11-04

Family

ID=40468754

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2010525114A Pending JP2010539192A (ja) 2007-09-18 2008-09-18 ノロウイルスに対して防御免疫応答を付与する方法
JP2014095094A Active JP6296885B2 (ja) 2007-09-18 2014-05-02 ノロウイルスに対して防御免疫応答を付与する方法
JP2016149168A Active JP6615063B2 (ja) 2007-09-18 2016-07-29 ノロウイルスに対して防御免疫応答を付与する方法
JP2019107207A Withdrawn JP2019163328A (ja) 2007-09-18 2019-06-07 ノロウイルスに対して防御免疫応答を付与する方法

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2014095094A Active JP6296885B2 (ja) 2007-09-18 2014-05-02 ノロウイルスに対して防御免疫応答を付与する方法
JP2016149168A Active JP6615063B2 (ja) 2007-09-18 2016-07-29 ノロウイルスに対して防御免疫応答を付与する方法
JP2019107207A Withdrawn JP2019163328A (ja) 2007-09-18 2019-06-07 ノロウイルスに対して防御免疫応答を付与する方法

Country Status (9)

Country Link
US (5) US10130696B2 (enExample)
EP (1) EP2190471A4 (enExample)
JP (4) JP2010539192A (enExample)
KR (2) KR20150129042A (enExample)
CN (2) CN104740624B (enExample)
AU (1) AU2008302276B2 (enExample)
CA (1) CA2698397C (enExample)
SG (2) SG10201601660YA (enExample)
WO (1) WO2009039229A2 (enExample)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014510073A (ja) * 2011-03-11 2014-04-24 マクマスター・ユニヴァーシティ ヒストンデアセチラーゼ阻害剤を含むワクチン接種法
JP2014520852A (ja) * 2011-07-11 2014-08-25 タケダ ワクチン，インコーポレイテッド 非経口ノロウイルスワクチン製剤
WO2015004995A1 (ja) * 2013-07-12 2015-01-15 株式会社Ｕｍｎファーマ ノロウイルスのウイルス様粒子を含む医薬組成物
WO2015093452A1 (ja) 2013-12-16 2015-06-25 武田薬品工業株式会社 マイクロニードル
JP2017178890A (ja) * 2016-03-31 2017-10-05 富山県 自然免疫を活性化する粘膜ワクチン用アジュバント
JP2018526437A (ja) * 2015-08-28 2018-09-13 オロジー バイオサーヴィシズ、インク． ノロウイルスワクチン
JP2021514391A (ja) * 2018-02-15 2021-06-10 アイコン ジェネティクス ゲーエムベーハー ノロウイルスに対する免疫応答を生成するための免疫原性組成物及びワクチン
JP2022514759A (ja) * 2018-12-20 2022-02-15 タケダ ワクチン，インコーポレイテッド ノロウイルスワクチン製剤及び方法
WO2023176206A1 (ja) 2022-03-18 2023-09-21 デンカ株式会社 リンカーにより連結されたカプシドタンパク質を含むウイルス様粒子

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2577833T3 (es) 2006-09-29 2016-07-19 Takeda Vaccines, Inc. Formulaciones de vacuna para norovirus
HUE028605T2 (en) 2007-03-14 2016-12-28 Takeda Vaccines Inc Cleaning virus-like particles
SG10201601660YA (en) 2007-09-18 2016-04-28 Takeda Vaccines Inc Method of conferring a protective immune response to norovirus
US20100266636A1 (en) 2007-09-18 2010-10-21 Ligocyte Pharmaceuticals, Inc. Method of conferring a protective immune response to norovirus
KR101793161B1 (ko) 2008-08-08 2017-11-03 다케다 백신즈 인코포레이티드 강화된 교차 반응성을 가진 복합체 캡시드 아미노산 서열들을 포함하는 바이러스-유사 입자들
WO2010111586A2 (en) 2009-03-27 2010-09-30 Arizona Board Of Regents Acting For And On Behalf Of Arizona State University Mucosal immunization
JP5804453B2 (ja) * 2009-05-14 2015-11-04 国立大学法人 東京大学 結晶性ポリオール微粒子及びその調製方法
US9439958B2 (en) * 2009-12-23 2016-09-13 Arizona Board Of Regents Acting For And On Behalf Of Arizona State University Stabilized virus like particles having enhanced mucosal immunogenicity
CA2804501C (en) 2010-07-06 2021-01-26 Novartis Ag Noro virus derived immunogenic compositions and methods
FI122520B (fi) * 2010-10-15 2012-03-15 Vesna Blazevic Noroviruksen kapsidi ja rotaviruksen VP6-proteiini käytettäväksi yhdistelmärokotteena
AU2012323189A1 (en) * 2011-10-12 2014-03-06 Alpha-O Peptides Ag Self-assembling peptide nanoparticles as vaccines against infection with norovirus
CN102559616B (zh) * 2012-02-24 2014-01-01 河南科技大学 一种含诺如病毒rna片段的假病毒颗粒及其制备方法
CA2876495C (en) 2012-06-21 2023-10-17 Northwestern University Peptide conjugated particles
JOP20130186B1 (ar) 2012-06-22 2021-08-17 Takeda Vaccines Montana Inc تنقية الجزيئات الشبيهة بالفيروسات
US20150086592A1 (en) * 2013-09-25 2015-03-26 Sequoia Sciences, Inc Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
AU2014329403B2 (en) 2013-10-03 2020-10-08 Takeda Vaccines, Inc. Methods of detection and removal of rhabdoviruses from cell lines
JP2017507968A (ja) * 2014-03-12 2017-03-23 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 粘膜送達用のリポソーム組成物
CN107184970A (zh) * 2017-02-16 2017-09-22 北京生物制品研究所有限责任公司 口服诺如病毒亚单位疫苗及lt作为该疫苗佐剂的用途
US20210308249A1 (en) * 2018-08-20 2021-10-07 Takeda Vaccines, Inc. Vlp formulations
EP4340874A1 (en) 2021-05-21 2024-03-27 Takeda Vaccines, Inc. Solid composition, freeze-drying method and glass vial
CN115677838A (zh) * 2021-07-29 2023-02-03 成都康华生物制品股份有限公司 六价诺如病毒VLPs疫苗及其制备方法
WO2025076792A1 (en) * 2023-10-12 2025-04-17 Chengdu Kanghua Biological Product Co., Ltd. Methods of preparing norovirus vaccine with low amounts of adjuvant

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6572862B1 (en) * 1989-11-08 2003-06-03 Baylor College Of Medicine Methods and reagents to detect and characterize Norwalk and related viruses
AU1893592A (en) 1991-03-25 1992-10-21 Board Of Trustees Of The Leland Stanford Junior University Norwalk virus human gastroenteritis agent and molecular cloning of corresponding cdnas
CA2133339A1 (en) 1992-04-08 1993-10-09 Jennifer S. Rota Wild-type measles virus glycoproteins: vaccine and detection method therefor
US5788970A (en) 1994-03-29 1998-08-04 The University Of Maryland College Park Chimeric infectious bursal disease virus CDNA clones, expression products and vaccines based thereon
ATE328068T1 (de) 1994-05-16 2006-06-15 Merck & Co Inc Papillomavirus vakzine
US5645051A (en) * 1995-04-21 1997-07-08 Dura Pharmaceuticals, Inc. Unit dose dry powder inhaler
US5861241A (en) * 1995-08-16 1999-01-19 University Of Massachusetts Monoclonal antibodies for detecting Norwalk virus
GB9525083D0 (en) * 1995-12-07 1996-02-07 Danbiosyst Uk Vaccine compositions
US5834015A (en) 1996-09-11 1998-11-10 Albany Medical College Protein-lipid vesicles and autogenous vaccine comprising the same
US5953727A (en) 1996-10-10 1999-09-14 Incyte Pharmaceuticals, Inc. Project-based full-length biomolecular sequence database
US6491919B2 (en) * 1997-04-01 2002-12-10 Corixa Corporation Aqueous immunologic adjuvant compostions of monophosphoryl lipid A
IL132201A0 (en) 1997-04-08 2001-03-19 Merck & Co Inc Stabilized human papillomavirus formulations
WO1998050071A1 (en) 1997-05-01 1998-11-12 Chiron Corporation Use of virus-like particles as adjuvants
US20040265377A1 (en) * 1997-10-27 2004-12-30 Harry Seager Solid dispersing vaccine composition for oral delivery
PL347472A1 (en) * 1998-08-14 2002-04-08 Merck & Co Inc Process for purifying human papillomavirus virus-like particles
AU770809B2 (en) 1998-12-17 2004-03-04 Merck Sharp & Dohme Corp. Synthetic virus-like particles with heterologous epitopes
KR20010093290A (ko) 1999-02-05 2001-10-27 폴락 돈나 엘. 사람 파필로마바이러스 백신 제제
EP1186890B1 (en) 1999-06-22 2013-01-02 Japan as Represented by Director-General of National Institute of Infectious Diseases Srsv detection kit
GB0118249D0 (en) 2001-07-26 2001-09-19 Chiron Spa Histidine vaccines
US7041500B2 (en) * 2002-02-14 2006-05-09 Novavax, Inc. Insect cell line
GB0206360D0 (en) 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
GB0206359D0 (en) 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
WO2003087327A2 (en) 2002-04-11 2003-10-23 Medimmune Vaccines, Inc. Preservation of bioactive materials by freeze dried foam
GB0302218D0 (en) 2003-01-30 2003-03-05 Chiron Sri Vaccine formulation & Mucosal delivery
CA2486118A1 (en) 2002-06-07 2003-12-18 Large Scale Biology Corporation Flexible vaccine assembly and vaccine delivery platform
BR0311995A (pt) 2002-06-20 2005-04-05 Cytos Biotechnology Ag Partìculas semelhantes a vìrus empacotadas para o uso como adjuvantes: método de preparação e uso
DE602004020189D1 (de) 2003-01-30 2009-05-07 Novartis Vaccines & Diagnostic Adjuvante influenza-vakzine
JP2006518748A (ja) 2003-02-20 2006-08-17 ベクトン・ディキンソン・アンド・カンパニー 改良されたワクチン接種のための大気圧噴霧凍結乾燥によって作製される組換えブドウ球菌エンテロトキシンｂ（＜ｓｂ＞ｒ＜／ｓｂ＞ｓｅｂ）の粉末処方物
US8592197B2 (en) 2003-07-11 2013-11-26 Novavax, Inc. Functional influenza virus-like particles (VLPs)
US7879338B2 (en) * 2003-07-21 2011-02-01 Boyce Thompson Institute For Plant Research Vectors and methods for immunization against norovirus using transgenic plants
US20050152911A1 (en) 2003-09-24 2005-07-14 Montana State University Norovirus monoclonal antibodies and peptides
WO2005037223A2 (en) * 2003-10-15 2005-04-28 Brigham And Women's Hospital, Inc. Methods and compositions for immunomodulation
US20050215501A1 (en) * 2003-10-24 2005-09-29 Coley Pharmaceutical Group, Inc. Methods and products for enhancing epitope spreading
FR2863890B1 (fr) 2003-12-19 2006-03-24 Aventis Pasteur Composition immunostimulante
US7481997B1 (en) * 2004-02-12 2009-01-27 Montana State University Snow mountain virus genome sequence, virus-like particles and methods of use
US20050260225A1 (en) * 2004-05-18 2005-11-24 Goldberg Joanna B Intranasal recombinant Salmonella vaccine encoding heterologous polysaccharide antigens
CU23496A1 (es) 2004-09-03 2010-02-23 Ct Ingenieria Genetica Biotech Composición vacunal contra el virus de la hepatitis c
WO2006044857A2 (en) 2004-10-20 2006-04-27 Acambis Inc. Vaccines against japanese encephalitis virus and west nile virus
GB0428394D0 (en) 2004-12-24 2005-02-02 Chiron Srl Saccharide conjugate vaccines
EP1846028A4 (en) 2005-01-05 2010-06-30 Philadelphia Health & Educatio TRANSPORT, BIOACTIVE SUBSTANCES AND VIRAL VACCINES
US8168771B2 (en) 2005-01-31 2012-05-01 The Johns Hopkins University Use of consensus sequence as vaccine antigen to enhance recognition of virulent viral variants
JP2008530245A (ja) 2005-02-18 2008-08-07 ノバルティス ヴァクシンズ アンド ダイアグノスティクス， インコーポレイテッド 尿路病原性菌株由来の抗原
PL1868642T3 (pl) 2005-03-18 2013-10-31 Cytos Biotechnology Ag Białka fuzyjne alergenów kocich i ich zastosowania
CN101287489A (zh) 2005-06-01 2008-10-15 陶氏环球技术公司 多价病毒样颗粒的生产
EP1736538A1 (en) 2005-06-21 2006-12-27 Cytos Biotechnology AG Process for the preparative purification of virus-like-particles (VLPs)
AU2006335256B2 (en) 2005-11-22 2012-10-18 Novartis Vaccines And Diagnostics, Inc. Norovirus and sapovirus antigens
JP2007145775A (ja) 2005-11-29 2007-06-14 Falco Life Science:Kk ノロウイルスｇｉの高感度検出方法
ES2577833T3 (es) 2006-09-29 2016-07-19 Takeda Vaccines, Inc. Formulaciones de vacuna para norovirus
PL2121011T3 (pl) 2006-12-06 2014-10-31 Novartis Ag Szczepionki zawierające antygeny czterech szczepów wirusa grypy
HUE028605T2 (en) 2007-03-14 2016-12-28 Takeda Vaccines Inc Cleaning virus-like particles
SG10201601660YA (en) 2007-09-18 2016-04-28 Takeda Vaccines Inc Method of conferring a protective immune response to norovirus
US20100266636A1 (en) 2007-09-18 2010-10-21 Ligocyte Pharmaceuticals, Inc. Method of conferring a protective immune response to norovirus
KR101793161B1 (ko) 2008-08-08 2017-11-03 다케다 백신즈 인코포레이티드 강화된 교차 반응성을 가진 복합체 캡시드 아미노산 서열들을 포함하는 바이러스-유사 입자들
WO2010084298A1 (en) 2009-01-22 2010-07-29 Pharmathene Uk Limited Stable vaccine compositions and methods of use
ES2552383T3 (es) 2009-02-10 2015-11-27 Novartis Ag Regímenes de vacuna de la gripe para cepas asociadas a pandemias
US20110070260A1 (en) 2009-09-09 2011-03-24 Baric Ralph S Multivalent Immunogenic Compositions Against Noroviruses and Methods of Use
CA2787666A1 (en) 2010-01-21 2011-07-28 Ligocyte Pharmaceuticals, Inc. Targeted heterologous antigen presentation on calicivirus virus-like particles
CN102905728B (zh) 2010-05-26 2015-11-25 西莱克塔生物科技公司 具有不偶合的佐剂的纳米载体组合物
EP3299030B1 (en) 2011-07-11 2022-06-08 Takeda Vaccines, Inc. Parenteral norovirus vaccine formulations
JOP20130186B1 (ar) 2012-06-22 2021-08-17 Takeda Vaccines Montana Inc تنقية الجزيئات الشبيهة بالفيروسات
JP2019505498A (ja) 2015-12-16 2019-02-28 ザ・ウォルター・アンド・エリザ・ホール・インスティテュート・オブ・メディカル・リサーチ Ｎｋ細胞におけるサイトカイン誘導性ｓｈ２タンパク質の阻害
GB2573406B (en) 2016-10-18 2021-11-10 Univ Minnesota Tumor infiltrating lymphocytes and methods of therapy
CN112292390A (zh) 2018-05-03 2021-01-29 得克萨斯大学体系董事会 经工程改造以在免疫检查点阻断的情况下表达嵌合抗原受体的自然杀伤细胞
US20210308249A1 (en) 2018-08-20 2021-10-07 Takeda Vaccines, Inc. Vlp formulations
AR117462A1 (es) 2018-12-20 2021-08-04 Takeda Vaccines Inc Vacuna contra norovirus, formulaciones y métodos
EP3924467A1 (en) 2019-02-15 2021-12-22 Editas Medicine, Inc. Modified natural killer (nk) cells for immunotherapy

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
JPN6013004327; ＬｉｇｏＣｙｔｅ　Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，　Ｉｎｃ．: 'ＬＩＧＯＣＹＴＥ　ＰＨＡＲＭＡＣＥＵＴＩＣＡＬＳ　ＩＮＩＴＩＡＴＥＳ　Ｕ．Ｓ．　ＣＬＩＮＩＣＡＬ　ＴＲＩＡＬ　ＯＦ　ＮＯＲＯＶＩＲＵＳ　ＶＡＣＣＩＮＥ' ［ｏｎｌｉｎｅ］ , 20070403 *
JPN6013004328; Ｖａｃｃｉｎｅ Ｖｏｌ．２１，　Ｎｏ．５-６, 2003, ｐ．３７６-３８５ *
JPN6013004329; Ｖａｃｃｉｎｅ Ｖｏｌ．２２，　Ｎｏ．９-１０, 2004, ｐ．１０７９-１０８６ *
JPN6013004330; Ｂｉｏｍｏｌｅｃｕｌａｒ　Ｅｎｇｉｎｅｅｒｉｎｇ Ｖｏｌ．１８，　Ｎｏ．３, 2001, ｐ．６９-８５ *
JPN6013004332; Ｖａｃｃｉｎｅ Ｖｏｌ．２４，　Ｎｏ．２４, 2006, ｐ．５２２０-５２３４ *

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9821054B2 (en) 2011-03-11 2017-11-21 Turnstone Limited Partnership Method of vaccination comprising a histone deacetylase inhibitor
JP2014510073A (ja) * 2011-03-11 2014-04-24 マクマスター・ユニヴァーシティ ヒストンデアセチラーゼ阻害剤を含むワクチン接種法
JP2014520852A (ja) * 2011-07-11 2014-08-25 タケダ ワクチン，インコーポレイテッド 非経口ノロウイルスワクチン製剤
JP2017214357A (ja) * 2011-07-11 2017-12-07 タケダ ワクチン，インコーポレイテッド 非経口ノロウイルスワクチン製剤
WO2015004995A1 (ja) * 2013-07-12 2015-01-15 株式会社Ｕｍｎファーマ ノロウイルスのウイルス様粒子を含む医薬組成物
WO2015093452A1 (ja) 2013-12-16 2015-06-25 武田薬品工業株式会社 マイクロニードル
JP2018526437A (ja) * 2015-08-28 2018-09-13 オロジー バイオサーヴィシズ、インク． ノロウイルスワクチン
JP7033534B2 (ja) 2015-08-28 2022-03-10 オロジー バイオサーヴィシズ、インク． ノロウイルスワクチン
US11596680B2 (en) 2015-08-28 2023-03-07 Resilience Government Services, Inc. Norovirus vaccine
JP2017178890A (ja) * 2016-03-31 2017-10-05 富山県 自然免疫を活性化する粘膜ワクチン用アジュバント
JP2021514391A (ja) * 2018-02-15 2021-06-10 アイコン ジェネティクス ゲーエムベーハー ノロウイルスに対する免疫応答を生成するための免疫原性組成物及びワクチン
US11633467B2 (en) 2018-02-15 2023-04-25 Icon Genetics Gmbh Immunogenic composition and vaccine for generating an immune response to norovirus
JP2022514759A (ja) * 2018-12-20 2022-02-15 タケダ ワクチン，インコーポレイテッド ノロウイルスワクチン製剤及び方法
WO2023176206A1 (ja) 2022-03-18 2023-09-21 デンカ株式会社 リンカーにより連結されたカプシドタンパク質を含むウイルス様粒子
KR20240145520A (ko) 2022-03-18 2024-10-07 덴카 주식회사 링커에 의해 연결된 캡시드 단백질을 포함하는 바이러스 유사입자

Also Published As

Publication number Publication date
CN101918028B (zh) 2015-01-07
US20240316175A1 (en) 2024-09-26
US10688174B2 (en) 2020-06-23
WO2009039229A2 (en) 2009-03-26
CA2698397A1 (en) 2009-03-26
CA2698397C (en) 2018-03-27
CN104740624B (zh) 2018-04-24
EP2190471A2 (en) 2010-06-02
JP2014141528A (ja) 2014-08-07
AU2008302276B2 (en) 2013-10-10
US10130696B2 (en) 2018-11-20
WO2009039229A3 (en) 2009-09-03
US11826415B2 (en) 2023-11-28
EP2190471A4 (en) 2012-05-09
KR20100083150A (ko) 2010-07-21
US11040097B2 (en) 2021-06-22
CN101918028A (zh) 2010-12-15
JP2019163328A (ja) 2019-09-26
US20110182975A1 (en) 2011-07-28
US20220143169A1 (en) 2022-05-12
AU2008302276A1 (en) 2009-03-26
JP6615063B2 (ja) 2019-12-04
US20200345827A1 (en) 2020-11-05
SG184733A1 (en) 2012-10-30
CN104740624A (zh) 2015-07-01
HK1211473A1 (en) 2016-05-27
SG10201601660YA (en) 2016-04-28
JP6296885B2 (ja) 2018-03-20
KR20150129042A (ko) 2015-11-18
US20190381164A1 (en) 2019-12-19
JP2016196502A (ja) 2016-11-24

Similar Documents

Publication Publication Date Title
US11826415B2 (en) Method of conferring a protective immune response to Norovirus
JP6613259B2 (ja) 非経口ノロウイルスワクチン製剤
US9821049B2 (en) Method of conferring a protective immune response to Norovirus
US9861691B2 (en) Norovirus vaccine formulations
AU2014200084B2 (en) Method of conferring a protective immune response to norovirus
AU2016250345A1 (en) Method of conferring a protective immune response to norovirus
HK1211473B (en) Vaccine of conferring a protective immune response to norovirus

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110914

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20110914

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120921

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20120921

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130131

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130430

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130509

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130530

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20130530

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20140106

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140502

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20140707

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20140815